Cancers With NTRK, ROS1, or ALK Gene Fusions Clinical Trial
Official title:
Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions
| NCT number | NCT03066661 |
| Other study ID # | Entrectinib (RXDX-101) - EAP |
| Secondary ID | |
| Status | No longer available |
| Phase | |
| First received | |
| Last updated |
| Verified date | April 2019 |
| Source | Hoffmann-La Roche |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Expanded Access |
Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.
| Status | No longer available |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion - Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial - Willing and able to provide written, signed informed consent - Medically suitable for treatment with entrectinib (RXDX-101) Exclusion Criteria: - Currently enrolled in an ongoing clinical study with any other investigational agent |
| Country | Name | City | State |
|---|---|---|---|
| United States | 1-844-Startrk (782-7875) | San Diego | California |
| Lead Sponsor | Collaborator |
|---|---|
| Hoffmann-La Roche |
United States,